Display press release or media coverage on homepage

Aerial Biopharma Announces Closing of Second Tranche of Series A; Expects to Complete Phase 2b Trial for Narcolepsy Drug in 2013.

MORRISVILLE, NC –  (February 20, 2013) – Aerial BioPharma announced today that the company has completed the second tranche of its $12 million dollar Series A financing.  The company has now raised $9.5M, with the third and final tranche of the Series A to be completed in the fourth quarter of 2013.  The funding will allow the company to complete the Phase 2b trial for ADX-N05, the company’s lead product for the treatment of excessive daytime sleepiness associated with narcolepsy.  After positive, Phase 2a results for ADX-N05 in mid-2012, Aerial began enrolling the Phase 2b trial in...

Read More

Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition

Diazepam Nasal Spray, Pre-NDA Stage Epilepsy Product, Added to Acorda’s Neurology Pipeline ARDSLEY, N.Y.–(BUSINESS WIRE)–Dec. 21, 2012– Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition. “Diazepam Nasal Spray is an important addition to our pipeline and aligns with our core strategy to develop and commercialize products that...

Read More